

ARTISAN PARTNERS

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

Name of Product: Artisan Developing World Fund (Fund) - Class I Euro Accumulating Shares; a sub-fund of Artisan Partners Global Funds plc (Company)

PRIIP Manufacturer & Management Company: Waystone Management Company (IE) Limited

Investment Manager: Artisan Partners Limited Partnership

ISIN: IE00BDZT4Z52

Website: <u>www.artisanpartners.com</u>

Call + 353 1 619 2300 for more information.

The Central Bank of Ireland (CBI) is responsible for supervising Waystone Management Company (IE) Limited in relation to this Key Information Document.

Waystone Management Company (IE) Limited is authorised in Ireland and regulated by the Central Bank of Ireland (CBI).

## This Key Information Document is accurate as at 1 January 2024.

What is this product?

## Туре

This product is a sub-fund of an open-ended umbrella fund authorised by the CBI pursuant to the UCITS Regulations (as amended).

## Term

This investment has no maturity date. The Company has the right to terminate the product in a limited number of circumstances, as set out in the Prospectus. The PRIIP Manufacturer, Waystone Management Company (IE) Limited, is not entitled to terminate the product unilaterally.

## Objectives

The Fund seeks to achieve long-term capital appreciation by investing primarily in shares of publicly listed companies (equities) and other types of investments that are referenced to such equities (known generally as equity-linked securities). The Fund seeks to invest in equity securities or issuers that are domiciled in or economically tied to countries of the developing world, including companies based in developed markets. For this purpose, developing world includes countries that are included in any one of the Morgan Stanley Capital Index emerging or frontier markets indices or that are classified under a similar corresponding




Income and dividends of the Fund will be reinvested and rolled up into the value of your shares.

#### **Intended Retail Investor**

A typical investor in the Fund is an institutional or professional investor, being a corporate, pension fund, insurance company, public sector body such as a governmental, supranational agency or local authority, bank, other investment firm or any other intermediary. This may also include high net worth individuals and private wealth management advisers and firms.

## What are the risks and what could I get in return?



The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a mediumhigh risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact our capacity to pay you.

If the product currency differs from your investment currency, the following applies: Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above. Please refer to the "Risk Factors" section of the prospectus for details of other risks including emerging markets, currency, counterparty, liquidity, operational and derivatives risks.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

## **Performance Scenarios**

The figures shown include all the costs of the product itself, and includes the costs of your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

# What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment between June 2021 and December 2023.

The moderate scenario occurred for an investment in the benchmark between May 2015 and May 2020.

The favourable scenario occurred for an investment in the benchmark between February 2016 and February 2021.

# Recommended holding period: 5 years

Example Investme		If		
Scenarios		lf you exit after 1 year	lf you exit after 5 years	
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.			
Stress	What you might get back after costs	2,050 EUR	1,040 EUR	
	Average return each year	-79.47 %	-36.35 %	
Unfavourable	What you might get back after costs	5,700 EUR	6,890 EUR	
	Average return each year	-42.97 %	-7.18 %	
Moderate	What you might get back after costs	10,930 EUR	16,840 EUR	
	Average return each year	9.25 %	10.99 %	
Favourable	What you might get back after costs	19,870 EUR	34,580 EUR	
	Average return each year	98.67 %	28.16 %	
	Average return each year	98.07 %		

## What happens if Waystone Management Company (IE) Limited is unable to pay out?

The Management Company of the Fund has no obligation to pay out since the Fund design does not contemplate any such payment being made. You are not covered by any national compensation scheme. To protect you, the assets are held with a separate company, a depositary. Should the Fund default, the depositary would liquidate the investments and distribute the proceeds to the investors. In the worst case, however, you could lose your entire investment.

## What are the costs?

# The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

## Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- EUR 10,000 is invested.

	lf you exit after 1 year	lf you exit after 5 years
Total costs	133 EUR	1,148 EUR
Annual cost impact (*)	1.3%	1.5% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 12.5% before costs and 11.0% after costs.

# **Composition of costs**

One-off costs upon entry or ex	lf you exit after 1 year			
Entry costs	We do not charge an entry fee.	0 EUR		
Exit costs	We do not charge an exit fee for this product.	0 EUR		
Ongoing costs [taken each year]				
Management fees and other administrative or operating costs	1.1% of the value of your investment per year. This is an estimate based or actual costs over the last year for managing your investments.	n 113 EUR		
Transaction costs	0.2% of the value of your investment per year. This is an estimate of the cost incurred when we buy and sell the underlying investments of the product The actual amount will vary depending on how much we buy and sell.			
Incidental costs taken under specific conditions				
Performance fees	There is no performance fee for this product.	0 EUR		

# How long should I hold it and can I take money out early?

# **Recommended holding period: 5 years**

We have selected 5 years as the product invests for the medium to long term. You can sell your units in the product on any Dealing Day as defined in the Prospectus, by using one of the methods described in the Prospectus. If you sell some or all of your investment before 5 years you will not incur any additional costs by doing so.

## How can I complain?

You can send your complaint to the Fund's Management Company at 35 Shelbourne Rd, Ballsbridge, IE - Dublin, D04 A4E0, Ireland or by e-mail to complianceeurope@waystone.com. If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

# Other relevant information

You can access additional information about the Fund, such as the Prospectus, annual and semi-annual reports and further information at https://www.apgfunds-docs.com.

Past Performance and Performance Scenario information are available at:

https://globalfiling.com/files/ArtisanPartners/PERF/PASTPERF\_Artisan\_Developing\_World\_Fund.pdf

https://globalfiling.com/files/ArtisanPartners/PERF/PREVPERF\_IE00BDZT4Z52\_EN.pdf

Past performance data is presented for a period of up to 10 years where available, and performance scenario data is presented monthly. The details of the up-to-date remuneration policy of the Management Company, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of the persons responsible for awarding the remuneration and benefits, including the composition of the remuneration committee, are available on www.waystone.com/waystone-policies/, a paper copy will be made available free of charge upon request.

The cost, performance and risk calculations included in this key information document follow the methodology prescribed by EU rule.

